Literature DB >> 8872356

Effects of N-, P- and Q-type neuronal calcium channel antagonists on mammalian peripheral neurotransmission.

C E Wright1, J A Angus.   

Abstract

1. The effects of N-, P- and Q-type neuronal voltage-operated calcium (Ca2+) channel antagonists on neurotransmission were determined in a range of cardiovascular and urogenital tissues, as well as the diaphragm, isolated from rat or mouse. 2. The pharmacological tools chosen were omega-conotoxin GVIA (CTX GVIA), a selective N-type Ca2+ channel antagonist, the P-type channel blocker (< or = 100 nM) omega-agatoxin IVA (AGA IVA) and omega-conotoxin MVIIC (CTX MVIIC), a non-selective antagonist of N-, P- and Q-type channels. The effects of these antagonists on nerve-mediated responses were assessed in right atria, vasa deferentia, phrenic nerve-hemidiaphragms and small mesenteric arteries. 3. Rat mesenteric artery contractile responses to perivascular nerve stimulation were concentration-dependently inhibited by CTX GVIA (1-10 nM); inhibition was 92% with 10 nM. CTX MVIIC was > 100 fold less potent and only caused an inhibition of 46% at the highest concentration (1000 nM). AGA IVA (100 nM) had no effect. 4. In rat vas deferens stimulated at 0.05 Hz, CTX GVIA (10 nM) completely inhibited the twitch response and CTX MVIIC, about 100 fold less potent, caused total inhibition at 1000 nM. AGA IVA did not affect the twitch. In rat preparations stimulated at 20 Hz, a CTX GVIA-resistant (< or = 1000 nM) twitch response of 25% was apparent which could be blocked by 1000 nM AGA IVA or CTX MVIIC. In mouse vas deferens (20 Hz stimulation), CTX GVIA 10 nM caused an 87% inhibition of the twitch, the remainder being resistant to CTX GVIA, 100 nM. CTX MVIIC was only 10 fold less potent than CTX GVIA and completely inhibited the response at 1000 nM. AGA IVA (100 nM) inhibited the twitch by 55%. 5. The twitch response of the mouse phrenic nerve-hemidiaphragm was concentration-dependently inhibited by AGA IVA (1-100 nM); inhibition was 92% at 100 nM. CTX MVIIC was about 10 fold less potent than AGA IVA with an inhibition of 80% at 1000 nM. CTX GVIA was without effect. In the rat diaphragm preparation, AGA IVA (< or = 100 nM) and CTX GVIA (< or = 1000 nM) had little effect on the twitch response. CTX MVIIC (1000 nM) inhibited the twitch by 57%. 6. In rat and mouse right atria, sympathetic responses were concentration-dependently inhibited by CTX GVIA with almost complete block at 10-100 nM. CTX MVIIC was 100 fold less potent and caused complete inhibition at 1000 nM in the mouse preparation. AGA IVA did not affect atrial sympathetic responses. 7. These data suggest that N-type Ca2+ channels predominate in the control of sympathetic transmission in the mesenteric artery, vas deferens and right atrium. In the mouse vas deferens (and rat tissue at high stimulus frequency), P- and Q-type channels also mediate Ca2+ influx. P- and Q-type Ca2+ channels control neurosecretion at the motor endplate, with no role for N type channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872356      PMCID: PMC1915745          DOI: 10.1111/j.1476-5381.1996.tb15676.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.

Authors:  M J Mulvany; W Halpern
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

Review 2.  Repeated measurements and multiple comparisons in cardiovascular research.

Authors:  J Ludbrook
Journal:  Cardiovasc Res       Date:  1994-03       Impact factor: 10.787

3.  Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission.

Authors:  D B Wheeler; A Randall; R W Tsien
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

4.  Differential effects of omega-conotoxin GVIA and MVIIC on nerve stimulation induced contractions of guinea-pig ileum and rat vas deferens.

Authors:  J R Boot
Journal:  Eur J Pharmacol       Date:  1994-06-02       Impact factor: 4.432

5.  A new Conus peptide ligand for Ca channel subtypes.

Authors:  V D Monje; J A Haack; S R Naisbitt; G Miljanich; J Ramachandran; L Nasdasdi; B M Olivera; D R Hillyard; W R Gray
Journal:  Neuropharmacology       Date:  1993-11       Impact factor: 5.250

Review 6.  Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins.

Authors:  B M Olivera; G P Miljanich; J Ramachandran; M E Adams
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

Review 7.  Distinctive pharmacology and kinetics of cloned neuronal Ca2+ channels and their possible counterparts in mammalian CNS neurons.

Authors:  J F Zhang; A D Randall; P T Ellinor; W A Horne; W A Sather; T Tanabe; T L Schwarz; R W Tsien
Journal:  Neuropharmacology       Date:  1993-11       Impact factor: 5.250

8.  Differential effects of omega-conotoxin GVIA and tetrodotoxin on vasoconstrictions evoked by electrical stimulation and nicotinic receptor stimulation in canine isolated, perfused splenic arteries.

Authors:  L M Ren; T Nakane; S Chiba
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

9.  Transmitter release and presynaptic Ca2+ currents blocked by the spider toxin omega-Aga-IVA.

Authors:  D A Protti; O D Uchitel
Journal:  Neuroreport       Date:  1993-12-13       Impact factor: 1.837

10.  Effect of omega-agatoxin-IVA on autonomic neurotransmission.

Authors:  P M Lundy; R Frew
Journal:  Eur J Pharmacol       Date:  1994-08-11       Impact factor: 4.432

View more
  22 in total

1.  Effects of omega-conotoxin GVIA and diltiazem on double peaked vasoconstrictor responses to periarterial electric nerve stimulation in isolated canine splenic artery.

Authors:  X P Yang; S Chiba
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  The probability of quantal secretion near a single calcium channel of an active zone.

Authors:  M R Bennett; L Farnell; W G Gibson
Journal:  Biophys J       Date:  2000-05       Impact factor: 4.033

3.  Differential facilitation of N- and P/Q-type calcium channels during trains of action potential-like waveforms.

Authors:  Kevin P M Currie; Aaron P Fox
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

4.  Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays.

Authors:  C E Wright; A D Robertson; S L Whorlow; J A Angus
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

5.  Calcium in sympathetic varicosities of mouse vas deferens during facilitation, augmentation and autoinhibition.

Authors:  K L Brain; M R Bennett
Journal:  J Physiol       Date:  1997-08-01       Impact factor: 5.182

6.  Effects of Ca2+ concentration and Ca2+ channel blockers on noradrenaline release and purinergic neuroeffector transmission in rat tail artery.

Authors:  J A Brock; T C Cunnane
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  Calcium channel subtypes for cholinergic and nonadrenergic noncholinergic neurotransmission in isolated guinea pig trachea.

Authors:  Chung-Hung Shih; Hsin-Te Hsu; Kuo-Hsien Wang; Chih-Hsieh Shih; Wun-Chang Ko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-09-05       Impact factor: 3.000

8.  L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons.

Authors:  A Bonci; P Grillner; N B Mercuri; G Bernardi
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

9.  Central endogenous histamine modulates sympathetic outflow through H3 receptors in the conscious rabbit.

Authors:  Julian Charles; James A Angus; Christine E Wright
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Lack of effect of Z-butylidenephthalide on presynaptic N-type Ca²⁺ channels in isolated guinea-pig ileum.

Authors:  Marcelo Chen; Wun-Chang Ko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.